Latest From Achaogen Inc.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
The UK National Health Service is to test the world's first ‘subscription’ payment model to tempt drug makers to develop new products for resistant infections.
Long-time deputy John Farley becomes acting director of the Office of Antimicrobial Products. Cox, who served as the director of the office for more than a decade, joins Regeneron to serve as vice president of regulatory affairs.
Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Achaogen Inc.
- Senior Management
Blake Wise, CEO
Zeryn Sarpangal, CFO
Janet Dorling, Chief Commercial Officer
- Contact Info
Phone: (650) 800-3636
1 Tower Pl., Ste. 300
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.